Overexpression of COX2 appears to be both a marker and an effector of neural damage after a variety of acquired brain injuries, and in natural or pathological aging of the brain. COX2 inhibitors may be neuroprotective in the brain by reducing prostanoid and free radical synthesis, or by directing arachidonic acid down alternate metabolic pathways. The arachidonic acid shunting hypothesis proposes that COX2 inhibitors' neuroprotective effects may be mediated by increased formation of potentially beneficial eicosanoids. Under conditions where COX2 activity is inhibited, arachidonic acid accumulates or is converted to eicosanoids via lipoxygenases and cytochrome P450 (CYP) epoxygenases. Several P450 eicosanoids have been demonstrated to have beneficial effects in the brain and/or periphery. We suspect that arachidonic acid shunting may be as important to functional recovery after brain injuries as altered prostanoid formation per se. Thus, COX2 inhibition and arachidonic acid shunting have therapeutic implications beyond the suppression of prostaglandin synthesis and free radical formation.
Introduction
The role of cyclooxygenase-2 (COX2) and its inhibitors in the brain must be examined in the larger context of its role in arachidonic acid metabolism (Fig. 1) . Perturbations or insults to the brain activate phospholipases, releasing arachidonic acid from membrane stores (Dumuis et al., 1988; Gardiner et al., 1981) . Cyclooxygenase-2 catalyzes the conversion of arachidonic acid and molecular oxygen into vasoactive prostaglandins, producing reactive oxygen free radicals in the process. COX2 is the dominant player in a complex and interlocking metabolic pathway that converts a structural membrane lipid into a plethora of biologically active eicosanoids, many of which have opposing physiological activity. Moreover, there are several other related biomolecules (e.g., docosahexenoic acid and docosanoids, the endocannabinoids anandamide and 2-arachidonoyl glycerol, etc.) that further expand the scope of influence of COX2 in neurophysiological functions.
Inhibition of COX2 after pathological insult has been shown to benefit recovery in the brain and spinal cord (Nagayama et al., 1999; Resnick et al., 1998) . However, the mechanisms of COX2 in neuropathology are not well described. Our working hypothesis is that prolonged COX2 expression in the brain interferes with intrinsic neuroprotective mechanisms, contributing to the establishment of a ''vicious cycle'' in which cell death, rather than survival pathways dominate; and tissue damage is made worse by propagation of oxidative damage and chemotactic signals. Thus, we propose that COX2 inhibition blocks delayed cell death and neuroinflammation.
That COX2 inhibitors may function in the brain by shunting arachidonic acid down alternate metabolic pathways has been alluded to by Christie et al. (1999) 
